These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34388857)

  • 1. Pneumococcal vaccine effect on hospitalisation rates of pneumonia in children: A meta-analysis.
    Zhu X; Li X
    Int J Clin Pract; 2021 Nov; 75(11):e14739. PubMed ID: 34388857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of community-acquired pneumonia hospitalisations before the introduction of pneumococcal conjugate vaccine into Polish National Immunisation Programme (2009-2016): A nationwide retrospective database analysis.
    Gajewska M; Goryński P; Paradowska-Stankiewicz I; Lewtak K; Piotrowicz M; Urban E; Cianciara D; Wysocki MJ; Książek A; Izurieta P
    Vaccine; 2020 Jan; 38(2):194-201. PubMed ID: 31653527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
    Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
    BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.
    Vadlamudi NK; Patrick DM; Rose C; Sadatsafavi M; Hoang L; Marra F
    Vaccine; 2022 Feb; 40(7):1047-1053. PubMed ID: 35012778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children.
    Silva SR; Mello LM; Silva AS; Nunes AA
    Rev Paul Pediatr; 2016 Dec; 34(4):418-424. PubMed ID: 27108092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine.
    Georgalis L; Mozalevskis A; Martínez de Aragón MV; Garrido-Estepa M
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):575-583. PubMed ID: 27844262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.
    Gajewska M; Lewtak K; Goryński P; Piotrowicz M; Urban E; Paradowska-Stankiewicz I; Rutyna A; Nitsch-Osuch A
    Vaccine; 2024 May; 42(13):3257-3262. PubMed ID: 38641493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
    Takeuchi N; Naito S; Ohkusu M; Abe K; Shizuno K; Takahashi Y; Omata Y; Nakazawa T; Takeshita K; Hishiki H; Hoshino T; Sato Y; Ishiwada N
    Epidemiol Infect; 2020 Apr; 148():e91. PubMed ID: 32299523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
    Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
    Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine.
    Li ST; Tancredi DJ
    Pediatrics; 2010 Jan; 125(1):26-33. PubMed ID: 19948570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
    van Deursen AMM; Schurink-Van't Klooster TM; Man WH; van de Kassteele J; van Gageldonk-Lafeber AB; Bruijning-Verhagen PCJL; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2017 Dec; 35(51):7107-7113. PubMed ID: 29146381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules.
    Lee HY; Hsieh YC; Liu CC; Huang YC; Chang KY; Chi H; Chang LY; Huang YC; Huang LM;
    J Microbiol Immunol Infect; 2018 Apr; 51(2):199-206. PubMed ID: 29021105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
    Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
    N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina.
    López EL; Glatstein E; Ezcurra GC; Iacono M; Teplitz E; Garnero AV; Lazzarini DL; Vázquez M; Contrini MM
    J Pediatric Infect Dis Soc; 2018 Feb; 7(1):30-35. PubMed ID: 28339727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute lower respiratory infections in Indigenous infants in Australia's Northern Territory across three eras of pneumococcal conjugate vaccine use (2006-15): a population-based cohort study.
    Binks MJ; Beissbarth J; Oguoma VM; Pizzutto SJ; Leach AJ; Smith-Vaughan HC; McHugh L; Andrews RM; Webby R; Morris PS; Chang AB
    Lancet Child Adolesc Health; 2020 Jun; 4(6):425-434. PubMed ID: 32450122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia.
    Shen CF; Wang SM; Chi H; Huang YC; Huang LM; Huang YC; Lin HC; Ho YH; Hsiung CA; Liu CC;
    J Biomed Sci; 2020 Aug; 27(1):88. PubMed ID: 32814590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.